Related Experiment Videos
Studies in radiosensitizing effects of misonidazole and SR-2508 on C3H/He mouse mammary tumors
Abstract:
The radiosensitizing efficacy of SR-2508, a new 2-nitroimidazole, which is less neurotoxic than misonidazole (MISO) was studied using transplantable mammary carcinoma of C3H/He mice. Tumor responses to treatments were evaluated by growth-delay time assay. In single irradiations, the enhancement ratios of 0.5 mmole/kg of MISO and 1.5 mmole/kg of SR-2508, which were equitoxic to C3H/He mice, were 1.42 and 1.84 respectively. In fractionated irradiations with three fractions over two days or five fractions over four days, the enhancement ratios of 1.5 mmole/kg of SR-2508 were 1.40 and 1.34 respectively. On the other hand the enhancement ratios of MISO at the above mentioned dose in respective fractionated irradiations were 1.15 or 1.11. SR-2508 is considered promising as a hypoxic cell radiosensitizer for clinical use.
Insights
SR-2508, a novel radiosensitizer, shows greater efficacy than misonidazole (MISO) in enhancing radiation therapy for mouse mammary tumors. This new drug offers a promising alternative for clinical applications targeting hypoxic cells.
Area of Science:
- Oncology
- Radiation Oncology
- Pharmacology
Background:
- Hypoxic tumor cells are resistant to radiation therapy.
- Misonidazole (MISO) is a radiosensitizer but has neurotoxic side effects.
- Novel hypoxic cell radiosensitizers with improved safety profiles are needed for clinical applications.
Purpose of the Study:
- To evaluate the radiosensitizing efficacy of SR-2508, a new 2-nitroimidazole derivative.
- To compare the efficacy of SR-2508 with misonidazole (MISO) in a murine mammary carcinoma model.
- To assess the radiosensitizing effect of SR-2508 under both single and fractionated irradiation conditions.
Main Methods:
- Utilized a transplantable mammary carcinoma model in C3H/He mice.
- Assessed tumor response using the growth-delay time assay.
- Administered equitoxic doses of MISO and SR-2508 prior to irradiation.
- Evaluated radiosensitizing enhancement ratios for single and fractionated radiation doses.
Main Results:
- SR-2508 demonstrated superior radiosensitizing enhancement ratios compared to MISO in single irradiations (1.84 vs. 1.42).
- SR-2508 maintained significant radiosensitizing effects under fractionated irradiation schedules (enhancement ratios of 1.40 and 1.34).
- MISO showed minimal enhancement under fractionated irradiation (1.15 and 1.11).
Conclusions:
- SR-2508 exhibits potent radiosensitizing activity against hypoxic tumor cells.
- SR-2508 is more effective than MISO, particularly under fractionated irradiation regimens.
- SR-2508 is a promising candidate for clinical use as a hypoxic cell radiosensitizer.